A review of therapeutic agents for breast cancer with potentially radiosensitizing properties

Zhang, Z; Lim, C; Feng, Z

A review of therapeutic agents for breast cancer with potentially radiosensitizing properties

Zhang, Z Lim, C

Feng, Z

Permalink

Publisher:: KeAi Communications Co., Ltd.
Publication Type:: Journal Article
Citation:: Radiation Medicine and Protection, 2024
Issue Date:: 2024-03-06

Embargoed

	Filename	Size
	814B2024-2276-4F25-902A-543EE5EA2091 AM.pdf	1.6 MB		View/Open

Copyright Clearance Process

Recently Added
In Progress
Embargoed
Open Access

This item is currently unavailable due to the publisher's embargo.

The embargo period expires on 6 Mar 2026

Full metadata record

Field	Value	Language
dc.contributor.author	Zhang, Z
dc.contributor.author	Lim, C https://orcid.org/0000-0002-2837-0973
dc.contributor.author	Feng, Z
dc.date.accessioned	2024-03-13T23:49:05Z
dc.date.available	2024-03-06
dc.date.available	2024-03-13T23:49:05Z
dc.date.issued	2024-03-06
dc.identifier.citation	Radiation Medicine and Protection, 2024
dc.identifier.issn	2666-5557
dc.identifier.uri	http://hdl.handle.net/10453/176660
dc.description.abstract	Breast cancer is the most frequently diagnosed malignant tumor in women worldwide and the leading cause of cancer death. Radiotherapy for breast cancer is readily accepted and widely used in clinical practice. Potential limitations with radiotherapy include treatment resistance, side effects, and complications caused by high doses of irritation. The search has been on to locate an efficacious radiosensitizer. This review summarizes six currently approved pharmaceuticals that have also been investigated for off-label use as radiosensitizers in breast cancer.
dc.language	en
dc.publisher	KeAi Communications Co., Ltd.
dc.relation.ispartof	Radiation Medicine and Protection
dc.relation.isbasedon	10.1016/j.radmp.2024.03.002
dc.rights	info:eu-repo/semantics/embargoedAccess
dc.title	A review of therapeutic agents for breast cancer with potentially radiosensitizing properties
dc.type	Journal Article
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Health
pubs.organisational-group	University of Technology Sydney/Faculty of Health/IMPACCT
utslib.copyright.status	embargoed	*
pubs.consider-herdc	true
utslib.copyright.embargo	2026-03-06T00:00:00+1000Z
dc.date.updated	2024-03-13T23:49:04Z
pubs.publication-status	Published online

Abstract:

Breast cancer is the most frequently diagnosed malignant tumor in women worldwide and the leading cause of cancer death. Radiotherapy for breast cancer is readily accepted and widely used in clinical practice. Potential limitations with radiotherapy include treatment resistance, side effects, and complications caused by high doses of irritation. The search has been on to locate an efficacious radiosensitizer. This review summarizes six currently approved pharmaceuticals that have also been investigated for off-label use as radiosensitizers in breast cancer.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/176660